David Lin, MD
Cardiovascular Disease · Edina, MNNPI 1629090196
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (56.2%), food and beverage and education — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 78.9% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $1,395, more than ten times the $12 reported in 2019.
Across 19 payments — averaging $93.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$1K
- Abbott$190
- Stryker$170
- Regeneron Healthcare Solutions, Inc.$12
Across 46 payments — averaging $5516.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kiniksa Pharmaceuticals, Ltd.$252K
- Siemens Medical Solutions USA, Inc.$2K
What the payments were for
- Travel & lodging$99456%
- Food & beverage$76143%
- Education$121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 6 | $1,395 |
| Abbott | 4 | $190 |
| Stryker | 8 | $170 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
How this compares
$1,768 in reported general payments places this provider in the 55th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 21 | $454,026 |
| EliquisApixaban | 225 | $281,828 |
| EntrestoSacubitril/Valsartan | 64 | $93,322 |
| XareltoRivaroxaban | 44 | $63,075 |
| FarxigaDapagliflozin Propanediol | 25 | $31,640 |
| Repatha SureclickEvolocumab | 18 | $22,574 |
| Metoprolol Succinate | 214 | $3,299 |
| Atorvastatin Calcium | 137 | $2,071 |
| Rosuvastatin Calcium | 157 | $1,965 |
| Ezetimibe | 64 | $1,832 |
| Flecainide Acetate | 29 | $1,459 |
| Carvedilol | 109 | $1,393 |
| Ranolazine ErRanolazine | 14 | $1,376 |
| Omega-3 Acid Ethyl Esters | 12 | $1,179 |
| Bumetanide | 21 | $1,150 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Edina
- Christopher FoleyEdina$192K
- Eric ErnstEdina$63K
- Timinder BiringEdina$43K
- Jeffrey ChambersMinneapolis$3.2M
- Srijoy MahapatraRochester$1.2M
- Markus MeyerMinneapolis$786K
- Robert SchwartzMinneapolis$502K
- Robert VantasselMinneapolis$493K
- Charanjit RihalRochester$478K
- Amir LermanRochester$465K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.